This page shows the latest Brukinsa news and features for those working in and with pharma, biotech and healthcare.
Also in June, the company announced that its BTK inhibitor Brukinsa (zanubrutinib) was approved by the ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry
Results presented at EHA2021 virtual congress showed an improved overall response rate for Brukinsa of 78.3%. ... Of these patients, 207 were on Brukinsa treatment and 208 were on Imbruvica treatment.
The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial. ... The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial in patients with relapsed or refractory MZL.
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
Brukinsa was unable to demonstrate statistically significant superiority in complete response (CR) or very good partial response (VGPR) rates compared to Imbruvica. ... Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates,
However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).
More from news
Approximately 5 fully matching, plus 4 partially matching documents found.
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....